Advertisement

Topics

BRIEF-Basilea Pharmaceutica: expansion of BAL101553 clinical phase 1/2a oral formulation study

20:19 EST 1 Dec 2016 | Reuters

* Expands oncology drug candidate BAl101553 clinical phase 1/2a oral study to include glioblastoma patients Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Original Article: BRIEF-Basilea Pharmaceutica: expansion of BAL101553 clinical phase 1/2a oral formulation study

NEXT ARTICLE

More From BioPortfolio on "BRIEF-Basilea Pharmaceutica: expansion of BAL101553 clinical phase 1/2a oral formulation study"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...